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Abstract
Theω-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA), in the free fatty acid (FFA) form, hasbeendemonstrated
to reduce adenoma number and size in patients with familial adenomatous polyposis. However, the mechanistic
basis of the antineoplastic activity of EPA in the colorectum remains unclear. We tested the hypothesis that EPA-
FFA negativelymodulates synthesis of and signaling by prostaglandin (PG) E2 in human colorectal cancer (CRC) cells.
EPA-FFA induced apoptosis of cyclooxygenase (COX)-2–positive human HCA-7 CRC cells in vitro. EPA-FFA in cell
culture medium was incorporated rapidly into phospholipid membranes of HCA-7 human CRC cells and acted as
a substrate for COX-2, leading to reduced synthesis of PGE2 and generation of PGE3. Alone, PGE3 bound and acti-
vated the PGE2 EP4 receptor but with reduced affinity and efficacy compared with its “natural” ligand PGE2. How-
ever, in the presence of PGE2, PGE3 acted as an antagonist of EP4 receptor–dependent 3′,5′ cyclic adenosine
monophosphate induction in naturally EP4 receptor–positive LoVo human CRC cells and of resistance to apoptosis
in HT-29-EP4 human CRC cells overexpressing the EP4 receptor. We conclude that EPA-FFA drives a COX-2–
dependent “PGE2-to-PGE3 switch” in humanCRCcells and that PGE3 acts as a partial agonist at the PGE2 EP4 receptor.
Neoplasia (2010) 12, 618–627
Introduction
Cyclooxygenase (COX)–derived prostaglandin (PG) E2 signaling
is believed to play a critical role during colorectal carcinogenesis [1].
In vitro experiments have demonstrated that PGE2 promotes colorec-
tal cancer (CRC) cell proliferation and invasion, as well as resistance to
apoptosis [2]. PGE2 also has proangiogenic properties and may down-
regulate the host antitumor immune response [2]. In vivo, PGE2 has
been demonstrated to drive intestinal tumorigenesis in the ApcMin/+
mouse model of familial adenomatous polyposis (FAP) [3] and in a
rat model of carcinogen-induced CRC [4].
Epidemiological evidence and preclinical data suggest that omega
(ω)-3 polyunsaturated fatty acids (PUFAs), which are found in large
quantities in fish such as salmon and mackerel, have anti-CRC activity
[5]. The mechanism(s) by which the main ω-3 PUFAs in dietary fish
oil, namely 20:5ω3 eicosapentaenoic acid (EPA) and 22:6ω3 docosa-
hexaenoic acid (DHA), have antineoplastic activity remains unclear
[6]. One valid hypothesis is that the anti-CRC activity of EPA is
explained by negative modulation of COX-PGE2 signaling.
In “western” diets, the predominant substrate for both COX iso-
forms (“constitutive“ COX-1 and “inducible” COX-2) is the ω-6
PUFA 20:4ω6 arachidonic acid (AA), from which two-series PGs such
as PGE2 are synthesized [7]. However, EPA can incorporate into the
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phospholipid bilayer, displace AA, and acts as an alternative substrate
for the COX enzymes [7]. EPA turnover in vitro (measured as Vmax)
by COX-1 and COX-2 is 10% and 35%, respectively, of that for AA
[7]. Importantly, COX converts EPA into PGH3, rather than PGH2,
leading to production of equivalent three-series PGs such as PGE3
[7]. It has been demonstrated that EPA administration to COX-2–
positive A549 human lung cancer cells and BxPC-3 human pancreatic
cancer cells leads to synthesis of PGE3 at the expense of PGE2 [8,9].
More recently, ω-3 fish oil administration to rats was shown to be asso-
ciated with the appearance of PGE3 and a reduction in PGE2 levels
in colorectal mucosa [10], confirming that a “PGE2-to-PGE3 switch”
can occur in vivo.
Although a reduction in tissue levels of protumorigenic PGE2 alone
could explain the anticancer properties of EPA, it is possible that PGE3
per se could contribute to the antitumorigenic activity of EPA. Consis-
tent with this concept, Yang et al. [8] have demonstrated that exoge-
nous PGE3 increased apoptosis of A549 human lung cancer cells.
However, the mechanistic basis of the antiproliferative activity of
PGE3 was not explored in that study.
PGE2 signals through a family of four G protein–coupled receptors
termed EP1 to EP4 (reviewed in Sugimoto and Narumiya [11]). At
late stages of colorectal carcinogenesis (primary CRC growth and
metastasis), preclinical evidence suggests a predominant role for the
EP4 receptor in the protumorigenic activity of PGE2 [12]. EP4 recep-
tor expression is increased in mouse and human CRCs compared with
normal colorectal mucosa [13,14]. Moreover, PGE2-EP4 receptor
signaling promotes tumorigenic behavior (proliferation, resistance to
apoptosis, motility, and invasion) of human colorectal adenoma and
CRC cells in vitro [13,14], whereas pharmacological antagonism of
PGE2-EP4 receptor signaling has been demonstrated to inhibit trans-
plantable CRC cell tumor growth and liver metastasis in Balb/c mice
[15]. Funahashi et al. [9] recently concluded that EPA had anti-
proliferative activity against BxPC-3 human pancreatic cancer cells
through a mechanism involving the EP4 receptor on the basis that
EPA activity was abrogated by the selective EP4 receptor antagonist
ONO-AE3-208.
We have recently reported that EPA, in the free fatty acid (FFA)
form (which is better absorbed from the human small intestine than
EPA in the ethyl ester or triglyceride form [16]), 2 g daily for 6 months
reduces rectal polyp number and size in a randomized controlled trial
(RCT) of patients with FAP [17]. The aim of this study was to inves-
tigate the mechanistic basis of the antineoplastic activity of EPA-FFA
in the colorectum by testing the hypotheses that EPA-FFA drives a
switch from synthesis of PGE2 to PGE3 in human CRC cells and that
PGE3 acts through inhibition of EP4 receptor signaling, thereby con-
tributing to the apoptotic activity of EPA against human CRC cells.
Materials and Methods
Reagents and Antibodies
EPA-FFA andMiglyol 810 (mixed capric and capryllic acidmedium-
chain triglycerides, which were used as the placebo in the RCTof EPA
in FAP patients [17]) were kindly provided by SLA Pharma (Watford,
UK). EPA-FFA was extracted from 500 mg of enteric-coated ALFA
capsules using a sterile needle and diluted 1:100 in 95% (vol./vol.)
ethanol immediately before use. A working solution of EPA was al-
ways freshly prepared from a new capsule to avoid auto-oxidation.
AA (Sigma-Aldrich, Poole, UK) was dissolved in 95% (vol./vol.)
ethanol as a 200-mM stock solution and stored at −20°C. PGE2
(20 mM stock solution in dimethyl sulfoxide [DMSO]) was also ob-
tained from Sigma-Aldrich. PGE3 (10 mM stock solution in DMSO)
was obtained from Cayman Chemical Co (Ann Arbor, MI). Working
solutions of PGE3 were always freshly prepared from frozen stock that
was then discarded to avoid freeze-thaw degradation. All other EP re-
ceptor agonists and antagonists were used as described previously [14].
SC-236 was a kind gift from Pfizer, Inc (Groton, CT). Methoxyamine
HCl was obtained from Sigma-Aldrich, and all high-performance
liquid chromatography–grade solvents were purchased from Fisher
Scientific (Loughborough, UK).
Human embryonic kidney 293 cell EP4 and EP2 receptor
membranes and [3H]-PGE2 (185.6 Ci/mmol) were obtained from
PerkinElmer LAS Ltd (Bucks, UK).
Polyclonal rabbit antibody against the human EP4 receptor
(N-terminal) was obtained from Cayman Chemical Co. Polyclonal
goat anti–COX-2 antibody (C-19) was obtained from Santa Cruz
Biotechnology, Inc (Santa Cruz, CA), and mouse monoclonal anti-
chicken β-actin antibody was obtained from Sigma-Aldrich. IR Alexa
Fluor 488–and Alexa Fluor 594–conjugated secondary antibodies
were obtained from Molecular Probes (Invitrogen, Paisley, UK).
IRDye 700- and IRDye 800–conjugated secondary antibodies were
obtained from Tebu-Bio Ltd (Peterborough, UK).
Cell Culture
Human CRC cell lines were all obtained from ECACC (Porton
Down, UK) except mouse colon 26 (MC-26) cells, which were ob-
tained from the National Cancer Institute (Frederick, MD). All cells
were cultured in RPMI 1640 medium containing Glutamax supple-
mented with 10% (vol./vol.) heat-inactivated fetal bovine serum (all
Invitrogen), except LoVo cells, which were cultured in Ham’s F12
medium (Invitrogen) containing Glutamax supplemented with 10%
(vol./vol.) heat-inactivated fetal bovine serum. All cells were cultured
at 37°C in a humidified atmosphere containing 5% CO2. Cells were
routinely subcultured using 0.25% (wt./vol.) trypsin (Invitrogen).
Viable cells were counted using a hemocytometer in the presence of
0.04% (vol./vol.) trypan blue (Sigma-Aldrich).
Measurement of Apoptosis
Apoptosis was measured by counting 4% (wt./vol. in phosphate-
buffered saline) paraformaldehyde-fixed, nonadherent HCA-7 and
HT-29 human CRC cells as described and validated by us and other
groups [14,18–25].
Immunoblot Analysis
Cells were lysed in ice-cold RIPA buffer (Sigma-Aldrich) and then
passed through a QIAshredder homogenizer (Qiagen Ltd, Crawley,
UK). Sodium dodecyl sulfate–polyacrylamide gel electrophoresis was
performed using 15 μg of total protein, and protein was transferred
to polyvinylidene fluoride membranes. Membranes were blocked in
Odyssey Blocking Buffer (LI-COR Biosciences Ltd, Cambridge,
UK) for 1 hour before incubating with anti–COX-2 antibody diluted
1:1000 in 1:1 Odyssey Blocking Buffer–Tween–Tris-buffered saline
(TTBS) for 1 hour at 25°C. Membranes were washed 3 × 3 minutes
in TTBS followed by incubation with IRDye 700–labeled secondary
antibody (1:2500) diluted in 1:1 Odyssey Blocking buffer–TTBS. Af-
ter 3 × 3 minutes washes with TTBS, membranes were incubated with
anti–β-actin antibody (1:20,000), and IRDye 800–labeled secondary
antibody (1:2500) was diluted in 1:1 Odyssey Blocking buffer–TTBS
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as above. Membranes were visualized using an Odyssey Infrared Imag-
ing System and Odyssey v1.2 software (LI-COR).
Indirect Immunofluorescence
Immunofluorescence studies were performed with primary anti-
bodies (anti-EP4, 1:25; anti-V5, 1:200) diluted in PBS containing
1% (wt./vol.) dried skimmed milk and 0.1% (vol./vol.) of Tween-20
as described [14], except that coverslips were mounted in Prolong
Gold with 4′,6 diamidino-2-phenylindole (Invitrogen).
Assay of Intracellular 3′,5′ Cyclic Adenosine
Monophosphate Content
A total of 1 × 106 CRC cells were incubated overnight in triplicate
35-mm wells. Cells were pretreated with 50 μM rolipram for 10 min-
utes before addition of 10 μM ONO-AE3-208 (ONO Pharmaceuti-
cal Co Ltd, Osaka, Japan) for 45 minutes before addition of EP
receptor agonists. Intracellular 3′,5′ cyclic adenosine monophosphate
(cAMP) content was assayed using a Biotrak enzyme immunoassay
(GE Healthcare Amersham, Amersham, UK) using the nonacetyla-
tion protocol.
Measurement of PGE2 and PGE3 Levels in CRC
Cell–Conditioned Medium
PGE2 and PGE3 levels weremeasured in CRC cell–conditionedme-
dium by high-sensitivity immunoassay (R&DSystems Ltd, Abingdon,
UK) or liquid chromatography–tandem mass spectrometry (LC/MS/
MS) based on the method of Murphey et al. [26]. PGE2 and PGE3
standards were prepared by converting PGE2 and PGE3 to their
O-methyloxime derivatives. Methoximated samples were diluted to a
total volume of 10 ml with water adjusted to pH 3.0. The aqueous
sample was applied to a C-18 Isolute SPE cartridge (Kinesis, St Neots,
Cambridgeshire, UK), preconditioned with 5ml of methanol and 5ml
of water (pH 3.0). The SPE cartridge was washed with 10 ml of water
(pH 3.0) and 10 ml of heptane. PGs were then eluted from the car-
tridge with 10 ml of ethyl acetate, and any residual aqueous material
was removed from the eluate by aspiration. The eluate was evaporated
using a centrifugal evaporator, and the dried residue was resuspended
in 25μl of 95:5, 0.1 (vol./vol.) acetic acid–acetonitrile (mobile phase A).
LC was performed on an ACQUITY UPLC BEH C8 Column,
2.1 × 100mm, 1.7 μm (Waters,Milford,MA) attached to an ACQUITY
Ultra Performance LC (UPLC) System. Samples were separated by a
gradient of 60% to 10% of mobile phase A in mobile phase B (50:50,
0.1 [vol./vol.] acetic acid–acetonitrile) for 4 minutes (total sample run
time, 8 minutes) at a flow rate of 300 μl/min before delivery to a
bench-top tandem quadrupole mass spectrometer (Quattro Premier
XE; Waters) operating in multiple reaction monitoring mode. Capil-
lary and cone voltages were 3.5 kV and 20 V, respectively, with a col-
lision voltage of 16 V, with source and desolvation temperatures of
150°C and 300°C, respectively. Multiple reaction monitoring chan-
nels were established for PGE2 (m/z 380 → 267.9 and 380.0) and
PGE3 (m/z 378→ 265.9, 266.9, and 378.0).
Measurement of Fatty Acid Phospholipid Membrane Content
Fatty acid content in cell membranes was measured by gas
chromatography-mass spectrometry as described [17].
[ 3H]-PGE2 Binding Assay
EP4 receptor (20 μg/well) and EP2 receptor (10 μg/well) mem-
brane preparations were incubated with [3H]-PGE2, with or without
cold PGs, in 50 mM Tris pH 6.0 with 0.5% (wt./vol.) bovine se-
rum albumin in 200-μl reactions in a 96-well polystyrene microplate
(PerkinElmer) at 27°C for 1 hour. The samples were transferred to
a GF/B filter (PerkinElmer) presoaked in PBS with 0.5% (wt./vol.)
bovine serum albumin using a Tomtec cell harvester, and unbound
[3H]-PGE2 was removed by washing eight times with ice-cold 50 mM
Tris-HCl pH 7.4. The filter was left to dry overnight at room tem-
perature before counting using a liquid scintillation counter (Wallac
1450 MicroBeta, PerkinElmer).
Statistical Analysis
The significance of differences associated with EPA and PG treat-
ments was tested by one-way analysis of variance with least significant
difference post hoc analysis. Significance was assumed if P < .05.
Results
EPA-FFA Induces Apoptosis of HCA-7 Human CRC Cells
Wemeasured apoptosis of CRC cells by the established technique of
nonadherent cell counting, which has been previously validated by
fluorescence microscopy of 4′,6 diamidino-2-phenylindole–stained
cells [14,18–25] and is recognized to correlate strongly with other
apoptosis assays based on measurement of caspase-3/7 activity [25]
and appearance of cell surface annexin V [14].
EPA-FFA promoted apoptosis of HCA-7 human CRC cells in a
concentration-dependent manner (Figure 1A). EPA-FFA exposure
equivalent to 0.8 μmol/106 cells, which represents addition of a
200-μM absolute concentration of EPA-FFA into aqueous cell culture
medium, was associated with a significant increase in apoptosis of
HCA-7 human CRC cells above control cells (Figure 1A). By contrast,
an equivalent level of exposure to the ω-6 PUFA AA did not induce
apoptosis of HCA-7 human CRC cells (Figure 1B). Addition of the
same vol./vol. amount of capric/caprylic acid medium-chain triglycer-
ides (Miglyol 810), which were used as the placebo in the recent RCT
of EPA [17], to cell culture medium was also not associated with in-
creased apoptosis of HCA-7 human CRC cells (Figure 1C ).
EPA-FFA in Aqueous Cell Culture Medium Is Rapidly
Incorporated into CRC Cell Membranes
During the same 24-hour period, we demonstrated that EPA-
FFA was incorporated into HCA-7 human CRC cell phospholipid
membranes (Figure 2A). Exposure to EPA-FFA (0.8 μmol/106 cells)
for 24 hours led to a large increase in EPA content so that EPA re-
presented approximately 20% of the total PUFA content (Figure 2A).
There was also a corresponding decrease in membrane AA content
(Figure 2A). However, there was no evidence of EPA-DHA conver-
sion in HCA-7 human CRC cells during the short-term exposure to
EPA-FFA (Figure 2A).
EPA Incorporation Leads to Changes in E-type PG Synthesis
by HCA-7 Human CRC Cells
HCA-7 human CRC cells constitutively express high levels of
COX-2 protein and generate measurable levels of PGE2 in condi-
tioned medium [18]. Therefore, we investigated whether the proapop-
totic activity linked to EPA incorporation was associated with the
simultaneous changes in E-type PG synthesis in this human CRC cell
line using LC/MS/MS (Figure W1).
Exposure to EPA-FFA for 24 hours was associated with a dose-
dependent decrease in PGE2 synthesis during a subsequent 4-hour
620 EPA and Human Colorectal Cancer Cells Hawcroft et al. Neoplasia Vol. 12, No. 8, 2010
period (Figure 2B), such that PGE2 synthesis was inhibited by
greater than 90% by amounts of EPA-FFA that promoted apoptosis
(0.4-0.8 μmol/106 cells). In the presence of culture medium contain-
ing only the ethanol carrier, PGE3 was not detected in HCA-7 hu-
man CRC cell–conditioned medium (Figure 2B). However, addition
of EPA-FFA stimulated PGE3 synthesis by HCA-7 human CRC cells
(Figure 2B). Levels of PGE3 in conditioned medium were an order of
magnitude lower than the corresponding values for PGE2. Moreover,
there was no observable concentration-response relationship for
PGE3 synthesis. “Chronic” treatment of HCA-7 human CRC cells
with EPA-FFA for 14 days was not associated with any further increase
in PGE3 levels in the conditioned medium (data not shown), suggest-
ing that the PGE3 levels measured in short-term experiments after a
24-hour EPA-FFA exposure represent maximal PGE3 synthesis.
EPA-FFA–dependent PGE3 synthesis was also observed in MC-26
mouse CRC cells, which also constitutively express high levels of
COX-2 (data not shown). Pretreatment of HCA-7 human CRC cells
with the selective COX-2 inhibitor SC-236 reduced PGE3 synthesis
by 87%, confirming that EPA-FFA–induced PGE3 synthesis is pre-
dominantly a COX-2–dependent process (Figure 2C ).
Consistent with a role for changes in E-type PG levels in the pro-
apoptotic activity of EPA, HT-29-EP4 human CRC cells, which do
not generate detectable amounts of PGE2 or PGE3 in conditioned
medium [14], in either the absence or presence of EPA-FFA (data
not shown), were resistant to EPA-FFA–induced apoptosis (Figure 3).
Proapoptotic Activity of EPA-FFA Is Not Explained
by Decreased COX-2 Protein Expression or Reduced
PGE2 Synthesis
It has previously been reported that EPA treatment decreases
COX-2 gene expression in serum-starved HT-29 human CRC cells
[27]. Therefore, reduced COX-2 protein levels could account for
Figure 1. EPA-FFA induces apoptosis of HCA-7 human CRC cells. (A) Apoptosis of HCA-7 human CRC cells (measured by nonadherent cell
counting; [14]) after treatment with increasing amounts of EPA-FFA (quoted as micromoles per 106 cells exposure and the equivalent
working micromolar concentration below that) or the equivalent dilution (0.06% vol./vol.) of 95% (vol./vol.) ethanol carrier alone (con) to
0.8 μmol of EPA-FFA/106 cells (200 μM) for 24 hours after overnight incubation of 0.5 × 106 CRC in triplicate 35-mm wells. Columns and
bars represent themean and SEMof triplicate values, respectively. Data are representative of three independent experiments. *P< .01 for
the comparison with con and EPA-FFA exposure less than 0.4 μmol/106 cells (100 μM). (B) Apoptotic HCA-7 human CRC cell counts
after treatment with increasing amounts of AA (quoted as micromoles per 106 cells or the micromolar concentration) or the equivalent
dilution (0.06% vol./vol.) of 95% (vol./vol.) ethanol carrier alone (con) to 0.8 μmol of AA/106 cells (200 μM) for 24 hours. Columns and bars
represent the mean and SEM of triplicate values, respectively. (C) Comparison of the proapoptotic activity of EPA-FFA and Miglyol
810 (both 0.8 μmol/106 cells [200 μM] in 95% [vol./vol.] ethanol) on HCA-7 human CRC cells. Con represents the equivalent dilution
(0.06% vol./vol.) of 95% (vol./vol.) ethanol alone. Columns and bars represent the mean and SEM of triplicate values, respectively.
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reduced PGE2 synthesis by HCA-7 human CRC cells treated with
EPA-FFA. However, EPA exposure for 24 hours was not associated
with changes in levels of COX-2 protein in HCA-7 human CRC cells
(Figure 4A). Alternatively, reduced PGE2 synthesis could explain the
proapoptotic activity of EPA-FFA. Therefore, we tested whether ex-
ogenous PGE2 “rescued” HCA-7 human CRC cells from EPA-FFA–
induced apoptosis. In the absence of EPA-FFA, exogenously added
PGE2 significantly reduced spontaneous apoptosis of HCA-7 human
CRC cells (Figure 4B). Addition of 1 μM PGE2 partially “rescued”
HCA-7 humanCRC cells from the effect of EPA-FFA (a 15% decrease
in apoptosis), but the presence of 10 μM PGE2 did not alter EPA-
FFA–induced apoptosis (Figure 4B).
PGE3 Antagonizes the Protumorigenic Activity of PGE2 in
HT-29-EP4 Human CRC Cells
An alternative hypothesis is that PGE3, alone or in combination
with reduced levels of protumorigenic PGE2, underlies the proapop-
totic activity of EPA-FFA. For initial experiments involving addition
of exogenous PGE2 and/or PGE3, we used HT-29-EP4 human CRC
Figure 2. EPA-FFA incorporates into cell membranes and alters COX-2–dependent E-type PG synthesis in HCA-7 human CRC cells.
(A) Changes in the fatty acid content of HCA-7 human CRC cell membranes after exposure to EPA-FFA (0.8 μmol/106 cells or 200 μM)
or an equivalent dilution (0.06% [vol./vol.]) of 95% (vol./vol.) ethanol carrier alone (control) for 24 hours. Columns and bars represent the
mean and SEM of triplicate values, respectively. (B) PGE2 and PGE3 levels in medium conditioned by HCA-7 human CRC cells in the
absence or presence of EPA-FFA. PGE2 and PGE3 levels weremeasured by LC/MS/MS in medium conditioned by HCA-7 human CRC cells
for 4 hours after 24 hours of prior exposure to EPA-FFA. Con represents the equivalent dilution (0.06% vol./vol.) of 95% (vol./vol.) ethanol
alone. nd indicates not detected. Columns and bars represent themean and SEM of triplicate values, respectively. Data are representative
of three independent experiments. (C) The effect of SC-236 (1 μM) on EPA-FFA–dependent E-series PG synthesis by HCA-7 human CRC
cells. SC-236 was added to the culture medium 90 minutes before EPA-FFA exposure (0.8 μmol/106 cells or 200 μM) for 24 hours. Fresh
mediumwas conditioned for 4 hours as in panel B. The presence of SC-236 did not significantly change the viable cell number at the end of
the experiment (data not shown). Columns and bars represent the mean and SEM of triplicate values, respectively.
Figure 3. HT-29-EP4 human CRC cells are resistant to EPA-FFA-
induced apoptosis. Apoptosis of HT-29-EP4 human CRC cells mea-
sured by nonadherent cell counting [14] after treatment with
0.8 μmol per 106 cells (200 μM) EPA-FFA or 95% (vol./vol.) ethanol
carrier alone (0.06% [vol./vol.]) for 24 hours after overnight incuba-
tion of 1 × 106 CRC in triplicate 35-mm wells. Columns and bars
represent the mean and SEM of triplicate values, respectively. NS
indicates not statistically significant (unpaired t test).
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cells [14], thereby avoiding the confounding effect of endogenous
PGE2 production by CRC cells. As expected, PGE2 decreased sponta-
neous apoptosis of HT-29-EP4 cells compared with cells treated with
ethanol carrier alone (Figure 5A), as described previously [14]. How-
ever, equimolar amounts of PGE3 alone did not significantly affect
apoptosis of HT-29-EP4 cells (Figure 5A). Importantly, PGE3 abro-
gated the antiapoptotic activity of PGE2 when the two E-type PGs
were present together at equimolar concentrations. This phenomenon
Figure 4. Decreased COX-2 protein expression or decreased PGE2 synthesis alone does not explain the proapoptotic activity of EPA-FFA in
human CRC cells. (A) Immunoblot analysis of COX-2 and β-actin protein levels in HCA-7 human CRC cells. Total protein cell lysates were
obtained after treatment with 0.06% (vol./vol.) 95% (vol./vol.) ethanol alone (con) or differing amounts of EPA-FFA for 28 hours. Columns
and bars represent themean and SEMof fluorescence COX-2/β-actin ratios, respectively, in arbitrary units from two separate experiments.
A representative immunoblot is included below. (B) Apoptosis of HCA-7 human CRC cells measured by nonadherent cell counting. Cells
were cultured for 24 hours in the absence (0.06% [vol./vol.] dilution of 95% [vol./vol.] ethanol alone) or presence of 0.8 μmol per 106 cells
(200 μM) EPA-FFA with or without PGE2. Columns and bars represent the mean and SEM of triplicate values, respectively. *P< .05 for the
comparison with control cells.
Figure 5. PGE3 antagonizes the protumorigenic activity of PGE2 in human CRC cells. (A) Apoptosis of HT-29-EP4 humanCRC cellsmeasured
by nonadherent cell counting after treatment with PGE3 and PGE2, alone or in combination, for 24 hours. Columns and bars represent the
mean and SEM of triplicate values for each condition, respectively. Con represents DMSO carrier (0.1% vol./vol.) alone. *P < .05 for the
difference from cells treatedwith 0.1 μMPGE2 alone. (B) Apoptosis of HCA-7 human CRC cells measured by nonadherent cell counting after
treatment with 1 μM PGE3 and PGE2, alone or in combination, for 24 hours. Columns and bars represent the mean and SEM of triplicate
values for each condition, respectively. Con represents DMSO carrier (0.1% vol./vol.) alone. *P< .05 for the comparison with control cells.
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was most prominent at a PG concentration of 0.1 μM (Figure 5A).
Similar observations were made with HCA-7 human CRC cells, in
which 1 μMPGE2, but not PGE3, had significant antiapoptotic activity
(Figure 5B). In a similar manner to HT-29-EP4 cells, the combination
of PGE2 and PGE3 did not have an additive effect on the propensity of
HCA-7 human CRC cells to apoptosis (Figure 5B). However, PGE3 did
not antagonize PGE2 activity in HCA-7 human CRC cells to the degree
observed in HT-29-EP4 cells (Figure 5B), perhaps due to the high levels
of PGE2 already produced endogenously by these cells.
PGE3 Directly Binds and Activates the EP4 Receptor on
Human CRC Cells
Given the close structural similarity between PGE2 and PGE3, we
hypothesized that PGE3 antagonizes PGE2 activity by binding to
Figure 6. PGE3 binds and acts as a partial agonist at the EP4 receptor in human CRC cells. (A) The effect of “cold” PGE3 on [
3H]-PGE2
(20 nM) binding to purified EP4 and EP2 receptor membranes. Data represent the mean and SEM percentage specific binding (n = 3)
compared with a “no PGE3” control. (B) Competition of “cold” PGE3 or PGE2 (20 nM) with [
3H]-PGE2 binding to purified EP4 receptor mem-
branes. Data represent themean and SEMof triplicatemeasurements in counts perminute (cpm). (C) The effect of PGE3 on cAMP levels in
HT-29-EP4 human CRC cells at 5 minutes. Cells were preincubated with the phosphodiesterase inhibitor rolipram. Columns
and bars represent themean and SEM of triplicate values for each condition, respectively. Con represents 0.1% (vol./vol.) of DMSO carrier
alone. Levels of cAMP after stimulation with all three concentrations of PGE3 were significantly different from control cAMP levels
(P < .001). (D) The effect of PGE3 alone on cAMP levels in LoVo human CRC cells at 5 minutes, in the absence (−) or presence (+) of
an EP4 receptor antagonist (10 μM ONO-AE3-208 for 60 minutes). Columns and bars represent the mean and SEM of triplicate values
for each condition, respectively. Con represents 0.1% (vol./vol.) of DMSO carrier alone. *P < .01 for the differences in cAMP levels in the
absence and presence of ONO-AE3-208. (E) The effect of PGE3 and PGE2, alone or in combination, on cAMP levels in LoVo human CRC
cells at 5minutes. Columns and bars represent themean and SEMof triplicate values for each condition. Con represents 0.1% (vol./vol.) of
DMSO carrier alone. *P< .05 for the difference in cAMP levels between cells treated with PGE2 alone versus equimolar amounts of PGE2
and PGE3. **P< .01 for the difference in cAMP levels between cells treatedwith PGE2 alone versus equimolar amounts of PGE2 and PGE3.
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PGE2 EP receptors. Evidence is strongest for a role for EP4 and EP2
receptors in PGE2 signaling during colorectal carcinogenesis [12–
14,28,29]. Consistent with the concept that PGE3 abrogates PGE2
signaling through EP receptors, PGE3 competed with PGE2 (20 nM)
for binding to purified human EP4 receptor (half maximal inhibitory
concentration [IC50] = 48 nM) and, to a lesser extent, EP2 receptor
(IC50 = 310 nM) membrane preparations in radioligand binding assays
(Figure 6A).However, direct comparison of PGE3 and PGE2 in a radio-
ligand competition assay using a purified human EP4 receptor prep-
aration demonstrated that PGE3 bound the EP4 receptor with less
affinity than the “natural” ligand PGE2 across a range of PGE2 concen-
trations (Figure 6B).
Moreover, PGE3 treatment led to a concentration-dependent rise in
cAMP levels in our HT-29-EP4 human CRC cell model of EP4 recep-
tor overexpression [14], confirming that PGE3 can act as an EP4 re-
ceptor agonist (Figure 6C ). We also tested the effect of PGE3 on LoVo
human CRC cells, which do not synthesize PGE2 (detection limit
2 pg/ml per 105 cells; data not shown) and which naturally exhibit
predominant PGE2-EP4 receptor signaling (Figure W2). PGE3 also in-
duced a concentration-dependent rise in cAMP levels in EP4 receptor–
positive LoVo human CRC cells (Figure 6D). Cyclic AMP induction
by PGE3 was inhibited by preincubation with the selective EP4 recep-
tor antagonist ONO-AE3-208 [14], thus confirming EP4 receptor
agonist properties of PGE3 in a second “natural” human CRC cell line
(Figure 6D).
PGE3 Is a Partial Agonist of the EP4 Receptor in Human
CRC Cells
A direct comparison of EP4 receptor activation by PGE2 and PGE3
in LoVo human CRC cells demonstrated that, although PGE3 is an
agonist at the EP4 receptor, PGE3 is less potent at activating the EP4
receptor than PGE2 (Figure 6E) with a 50% effective dose (ED50) of
less than 100 nM, consistent with the lower binding affinity of PGE3
noted earlier (Figure 6B). In keeping with the effect of PGE3 on human
CRC cell apoptosis (Figure 5), exposure of equimolar amounts of PGE2
andPGE3 to LoVo humanCRC cells was not associatedwith an additive
effect on cAMP elevation (Figure 6E ). Instead, the combination of
PGE3 and PGE2 was associated with a lower cAMP response than either
ligand alone, suggesting a negative interaction between the three- and
two-series PGs (Figure 6E). Similar observations were made in HT-29-
EP4 human CRC cells (data not shown). Therefore, PGE3 is a partial
agonist at the EP4 receptor such that PGE3 alone acts as an EP4 ago-
nist, but in the presence of the natural ligand PGE2, it behaves as an
EP4 receptor antagonist. The partial agonist activity of PGE3 on EP4
receptor–dependent cAMP elevation is consistent with a decrease in
the antiapoptotic activity of PGE2 in the presence of PGE3 that was
observed in EP4 receptor–positive HT-29-EP4 (Figure 5A).
Discussion
We report, for the first time, that theω-3 PUFA EPA, in the FFA form,
reduces COX-2–dependent PGE2 synthesis and simultaneously drives
a “PGE2-to-PGE3 switch” in human CRC cells in vitro. We have also
elucidated that PGE3 antagonizes protumorigenic signaling at the EP4
receptor by its natural ligand PGE2 in human CRC cells. The relative
contributions of reduced PGE2 synthesis and PGE3 activity to the
anti-CRC effects of EPA in vivo remain to be determined. We did not
address potential COX-independent mechanisms of the antineoplastic
activity of EPA [5,6] in our experiments, including modulation of lipid
raft behavior and lipid peroxidation.
Although EPA has previously been demonstrated to induce apopto-
sis of human CRC cells [5,6], ours is the first report concerning the
proapoptotic activity of EPA-FFA formulation that has been shown
to have antineoplastic effects in humans with FAP [17]. Our data
are consistent with the increase in apoptotic cell frequency in normal
rectal mucosa, which was observed in a previous phase 2 trial of EPA-
FFA in patients with a history of “sporadic” colorectal adenomas [30].
Although EPA can act as a substrate for COX-2 with a KM value
similar to AA, enzymatic turnover values are approximately 35% those
of AA [31]. Therefore, in the absence of any short-term change in
COX-2 protein levels, reduced EPA substrate handling may explain
the combination of a marked dose-dependent decrease in PGE2 syn-
thesis with appearance of PGE3 at significantly lower levels than those
observed for PGE2. However, other factors are also likely to contribute
to “inefficient” E-type PG synthesis when EPA acts as a COX-2 sub-
strate, which may include decreased PGE synthase activity on PGH3
compared with PGH2 [31]. Studies are currently underway in our lab-
oratory that will address whether a similar magnitude “PGE2-to-PGE3
switch” occurs in EPA-FFA–treated mouse and human CRC tissue
in vivo. It is interesting to note that in the one published study that
has examined whether a tissue “PGE2-to-PGE3 switch” occurs in vivo,
colonic mucosal PGE2 levels were reduced by approximately 75%,
along with appearance of PGE3 (albeit at much lower concentra-
tions), in rats administered a fish oil– and pectin-containing diet [10].
Another important observation is that EPA, in the FFA form, is in-
corporated efficiently into membrane phospholipids of human CRC
cells when delivered into the aqueous cell culture medium. Our ob-
servations concur with those in murine epidermal cells [32], human
breast cancer cells [33], and human endothelial cells [34], in which
significant EPA incorporation occurred within 24 hours of addition
to the cell culture medium in an ethanol carrier. These in vitro find-
ings mirror the increase in the EPA content of rectal mucosa of FAP
patients, who received EPA-FFA 2 g daily for 6 months [17]. Not un-
expectedly, there was no evidence of ω-3 PUFA interconversion from
EPA to the other main ω-3 PUFA DHA in short-term cell culture,
which is likely explained by low elongase and Δ6-desaturase activi-
ties in intestinal epithelial cells necessary for EPA-DHA conver-
sion [35].
An important component of our study was a functional screen of
a panel of human CRC cells for dominant PGE2-EP4 receptor signal-
ing based on the identification of PGE2-dependent cAMP induc-
tion that could be inhibited by a selective EP4 receptor antagonist,
in combination with immunoreactive protein localization. Identifica-
tion of dominant PGE2-EP4 receptor activity has significant advan-
tages over previous semiquantitative reverse transcription–polymerase
chain reaction measurements of EP receptor messenger RNA ex-
pression, which have uncertain functional significance [29,36]. Our
functional screen identified LoVo and HCA-7 human CRC cells as ex-
hibiting predominant EP4 receptor–dependent induction of cAMP by
PGE2, for use in future in vitro studies of EP4 receptor function during
colorectal carcinogenesis, alongside stably transfected HT-29-EP4
cells [14].
Previous studies using stably transfected human embryonic kidney
293 cells expressing human EP receptors have demonstrated that
PGE3 acts as a partial agonist at EP1 to EP3 receptors, with the bind-
ing affinity and receptor activation potency of PGE3 being signifi-
cantly less than PGE2 [31]. However, the 3.5-fold decrease in affinity
and 6-fold decrease in potency (measured by cAMP induction) of
PGE3 (ED50 = 3.5 nM) compared with PGE2 (ED50 = 0.58 nM) at
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the EP4 receptor in 293 cells failed to reach statistical significance in
this study [30]. Our data confirm that PGE3 does indeed act as a par-
tial agonist at the EP4 receptor in human CRC cells, which naturally
express the EP4 receptor. PGE3 has been previously reported to act in
an EP4 receptor–dependent manner in BxPC-3 human pancreatic
cancer cells, although direct PGE3-EP4 receptor binding was not con-
firmed in this study [9].
Exogenous PGE3 has been reported to decrease proliferation of
COX-2–positive human A549 lung cancer cells and BxPC-3 human
pancreatic cancer cells [8,9] and decrease invasiveness of COX-2–
positive 70W human melanoma cells [37]. However, treatment with
PGE3 did not have any significant effect on the proliferation of NIH
3T3 fibroblasts [38] or nontransformed mouse mammary epithelial
cells [39] and actually stimulated interleukin 6 production by unacti-
vated mouse RAW264.7 macrophages, in a similar manner to PGE2
[38]. Partial agonist activity of PGE3 at EP receptors may explain these
discrepant findings such that exogenously added PGE3 has antagonist
properties on a background of ongoing PGE2-dependent signaling in
COX-2–positive cells but has stimulatory activity when present alone
with cells that do not synthesize PGE2.
Our novel insights into EPA-dependent alterations in E-type PG
synthesis and EP receptor signaling in human CRC cells have im-
portant implications for future translational human studies of the
anti-CRC activity of the ω-3 PUFA EPA. The role of COX-2 in EPA-
dependent alterations in PG synthesis suggests that combination ther-
apy of EPA with a COX-2 inhibitor could abrogate the antineoplastic
activity of both agents. Consistent with this concept, the selective
COX-2 inhibitor celecoxib and the nonselective COX inhibitor indo-
methacin have both been demonstrated to decrease the proapoptotic
and antiproliferative effects of EPA, respectively [8,40]. Therefore,ω-3
PUFA and selective COX-2 inhibitor treatment should only be con-
sidered for evaluation as a combination anticancer therapy with cau-
tion. Measurement of erythrocyte and/or tissue ω-3 PUFA levels is
established as a biomarker of ω-3 PUFA intake and bioavailability
[41,42]. However, the degree of membrane ω-3 PUFA incorporation
might not necessarily mirror bioactivity. We suggest that measurement
of PGE3 (or its stable metabolite) levels in tissue, plasma, or urine
should be investigated as a potential biomarker of COX-2–dependent
EPA activity and therapeutic response in clinical studies.
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Figure W1. LC/MS/MS measurement of PGE2 and PGE3 in HCA-7
human CRC cell–conditioned medium. (A) Chromatogram of au-
thentic PGE2 (100 ng/ml) and PGE3 (50 ng/ml) running at 5.7 and
5.0 minutes, respectively. (B) Chromatograms of extracted cell cul-
ture medium. The lower traces are PGE3 and PGE2 channels for
unconditioned medium. The top two traces are PGE3 and PGE2
channels for medium conditioned by cells cultured in the presence
of 95% (vol./vol.) ethanol carrier alone for 24 hours. Note the ab-
sence of a PGE3 peak and a large PGE2 peak. (C) Chromatograms
of extracted conditioned medium from cells cultured in the pres-
ence of EPA-FFA (0.2 μmol/106 cells [equivalent to a 50-μMconcen-
tration]) for 24 hours. PGE3 is now present in conditioned medium
along with lesser amounts of PGE2 compared with medium condi-
tioned in the absence of EPA-FFA (compare with B).
Figure W2. EP4 receptor signaling in human CRC cells. (A) Human CRC cell lines that generated a PGE2-induced increase in intracellular
cAMP at 5minutes were identified. (B) cAMP induction by PGE2 (1 μM)was inhibited by the EP4 receptor antagonist (EP4 antg) ONO-AE3-
208 (10 μM) but not mimicked by the EP2 receptor agonist butaprost (but; 1 μM) in LoVo, HCT116, and HCA-7 cells, confirming dominant
PGE2-EP4 receptor signaling in these human CRCcell lines (but not HRT18). (C) Immunofluorescence detection of EP4 receptor protein in i)
HT-29-EP4 cells (membranous colocalization [yellow] of anti-V5 tag [red] and EP4 receptor [green]), ii) and iii) LoVo cells demonstrating
cytoplasmic and membranous localization (arrowheads), and iv) PGE2 (1 μM)-treated LoVo cells demonstrating ligand-induced receptor
internalization (inset—no primary antibody control).
